Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine

Comprehensive Psychiatry

Volumn 55, Issue 3, 2014, Pages 708-713

  Kim, Jong Hoon ^a   Lee, Jinyoung ^a   Kim, Young Bo ^a   Han, Ah Young ^a  

^a Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FEMALE; FISHER EXACT TEST; HUMAN; MALE; MENTAL DISEASE; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; WELLBEING;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DEPRESSION; FEMALE; HUMANS; MALE; PERSONAL SATISFACTION; QUALITY OF LIFE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896494399     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2013.11.002     Document Type: Article

References (45)

1. W. de Millas, M. Lambert, and D. Naber The impact of subjective well-being under neuroleptic treatment on compliance and remission Dialogues Clin Neurosci 8 2006 131 136
2. M. Lambert, J.M. Haro, D. Novick, E.T. Edgell, L. Kennedy, and M. Ratcliffe et al. Olanzapine vs. other antipsychotics in actual out-patient settings: Six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study Acta Psychiatr Scand 111 2005 232 243
3. L. Hansson Determinants of quality of life in people with severe mental illness Acta Psychiatr Scand Suppl 429 2006 46 50
4. J.D. Huppert, K.A. Weiss, R. Lim, S. Pratt, and T.E. Smith Quality of life in schizophrenia: Contributions of anxiety and depression Schizophr Res 51 2001 171 180
5. K. Sim, R. Mahendran, S.G. Siris, S. Heckers, and S.A. Chong Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression Psychiatry Res 129 2004 141 147
6. A. Hofer, G. Kemmler, U. Eder, M. Edlinger, M. Hummer, and W.W. Fleischhacker Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects J Clin Psychiatry 65 2004 932 939
7. A. Karow, S. Moritz, M. Lambert, S. Schoder, and M. Krausz PANSS syndromes and quality of life in schizophrenia Psychopathology 38 2005 320 326
8. J.M. Narvaez, E.W. Twamley, C.L. McKibbin, R.K. Heaton, and T.L. Patterson Subjective and objective quality of life in schizophrenia Schizophr Res 98 2008 201 208
9. S.M. Eack, and C.E. Newhill Psychiatric symptoms and quality of life in schizophrenia: A meta-analysis Schizophr Bull 33 2007 1225 1237
10. J. Kreyenbuhl, S.C. Marcus, J.C. West, J. Wilk, and M. Olfson Adding or switching antipsychotic medications in treatment-refractory schizophrenia Psychiatr Serv 58 2007 983 990
11. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured Clinical Interview for DSM-IV Axis I Disorders Research Version (SCID-I) 1996 Biometrics Research, New York State Psychiatric Institute New York
12. D. Naber, S. Moritz, M. Lambert, F.G. Pajonk, R. Holzbach, and R. Mass et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs Schizophr Res 50 2001 79 88
13. R. Mizrahi, P. Rusjan, O. Agid, A. Graff, D.C. Mamo, and R.B. Zipursky et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia Am J Psychiatry 164 2007 630 637
14. L. de Haan, M. Weisfelt, P.M. Dingemans, D.H. Linszen, and L. Wouters Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale Psychopharmacology 162 2002 24 28
15. L. de Haan, L. Nimwegen, T. Amelsvoort, P. Dingemans, and D. Linszen Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia Pharmacopsychiatry 41 2008 125 128
16. D. Naber, M. Riedel, A. Klimke, E.U. Vorbach, M. Lambert, and K.U. Kühn et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia Acta Psychiatr Scand 111 2005 106 115
17. M. Lambert, B.G. Schimmelmann, D. Naber, A. Schacht, A. Karow, and T. Wagner et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia J Clin Psychiatry 67 2006 1690 1697
18. S.R. Kay, A. Fiszbein, and L.A. Opler The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
19. S.R. Kay, and L.A. Opler Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) 1988 Albert Einstein College of Medicine New York
20. J.H. Kim, S.Y. Kim, J. Lee, K.J. Oh, Y.B. Kim, and Z.H. Cho Evaluation of the factor structure of symptoms in patients with schizophrenia Psychiatry Res 197 2012 285 289
21. S.R. Marder, J.M. Davis, and G. Chouinard The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials J Clin Psychiatry 58 1997 538 546
22. W. Guy ECDEU Assessment Manual for Psychopharmacology, Revised 1976 US Department of Health, Education, and Welfare Bethesda, MD
23. A.T. Beck, C.H. Ward, M. Mendelson, J. Mock, and J. Erbauch An inventory for measuring depression Arch Gen Psychiatry 4 1961 561 571
24. W.W. Fleischhacker, J. Rabinowitz, G. Kemmler, M. Eerdekens, and A. Mehnert Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year Br J Psychiatry 187 2005 131 136
25. C.A. Galletly, C.R. Clark, A.C. McFarlane, and D.L. Weber Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine Psychiatry Res 72 1997 161 166
26. J.H. Kim, J.H. Ann, and M.J. Kim The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia Compr Psychiatry 51 2010 165 170
27. L. Renwick, D. Jackson, S. Foley, E. Owens, N. Ramperti, and C. Behan et al. Depression and quality of life in first-episode psychosis Compr Psychiatry 53 2012 451 455
28. W.K. Fakhoury, W. Kaiser, U.U. Roeder-Wanner, and S. Priebe Subjective evaluation: Is there more than one criterion? Schizophr Bull 28 2002 319 327
29. P.C. Bermanzohn, L. Porto, P.B. Arlow, S. Pollack, R. Stronger, and S.G. Siris Hierarchical diagnosis in chronic schizophrenia: A clinical study of co-occurring syndromes Schizophr Bull 26 2000 517 525
30. P.F. Liddle, T.R. Barnes, D.A. Curson, and M. Patel Depression and the experience of psychological deficits in schizophrenia Acta Psychiatr Scand 88 1993 243 247
31. P.F. Liddle, and T.R. Barnes The subjective experience of deficits in schizophrenia Compr Psychiatry 29 1988 157 164
32. D. Addington, J. Addington, and E. Maticka-Tyndale Assessing depression in schizophrenia: The Calgary Depression Scale Br J Psychiatry Suppl 22 1993 39 44
33. S.G. Siris, D. Addington, J.M. Azorin, I.R. Falloon, J. Gerlach, and S.R. Hirsch Depression in schizophrenia: Recognition and management in the USA Schizophr Res 47 2001 185 197
34. J. Waserman, and M. Criollo Subjective experiences of clozapine treatment by patients with chronic schizophrenia Psychiatr Serv 51 2000 666 668
35. A. Karow, and D. Naber Subjective well-being and quality of life under atypical antipsychotic treatment Psychopharmacology 162 2002 3 10
36. P. Mohr Quality of life in the long-term treatment and the role of second-generation antipsychotics Neuro Endocrinol Lett 28 Suppl. 1 2007 117 133
37. J. Moncrieff Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination Br J Psychiatry 183 2003 161 166
38. S. Pollack, J.A. Lieberman, W.W. Fleischhacker, M. Borenstein, A.Z. Safferman, and M. Hummer et al. A comparison of European and American dosing regimens of schizophrenic patients on clozapine: Efficacy and side effects Psychopharmacol Bull 31 1995 315 320
39. W.W. Fleischhacker, M. Hummer, M. Kurz, I. Kurzthaler, J.A. Lieberman, and S. Pollack et al. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects J Clin Psychiatry 55 Suppl. B 1994 78 81
40. Y.L. Tang, P.X. Mao, F. Jiang, Q. Chen, C.Y. Wang, and Z.J. Cai et al. Clozapine in China Pharmacopsychiatry 41 2008 1 9
41. C.H. Ng, S.A. Chong, T. Lambert, A. Fan, L.P. Hackett, and R. Mahendran et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels Int Clin Psychopharmacol 20 2005 163 168
42. D. Naber A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables Int Clin Psychopharmacol 10 Suppl. 3 1995 133 138
43. S. Moritz, M. Krausz, E. Gottwalz, M. Lambert, C. Perro, and S. Ganzer et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics Psychopathology 33 2000 48 51
44. D. Naber, and A. Karow Good tolerability equals good results: The patient's perspective Eur Neuropsychopharmacol 11 Suppl. 4 2001 S391 S396
45. L.N. Voruganti, and A.G. Awad Personal evaluation of transitions in treatment (PETiT): A scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia Schizophr Res 56 2002 37 46